Bioactivation of the pulmonary toxicants naphthalene and 1-nitronaphthalene by rat CYP2F4

被引:31
作者
Baldwin, RM [1 ]
Shultz, MA [1 ]
Buckpitt, AR [1 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA
关键词
D O I
10.1124/jpet.104.075440
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Naphthalene, a ubiquitous environmental contaminant, produces cytotoxicity in nonciliated bronchiolar epithelial (Clara) cells in mice; rats are refractory to lung cytotoxicity from naphthalene. In contrast, 1-nitronaphthalene is a potent toxicant in both species. Naphthalene is metabolized by CYP2F to a 1,2-epoxide, the first and obligate step in events leading to cytotoxicity. 1-Nitronaphthalene is metabolized to both the 5,6- and the 7,8-epoxides with the 7,8-epoxide predominating in lung. Previous studies have demonstrated recombinant CYP2F2 ( mouse) to efficiently metabolize both naphthalene and 1-nitronaphthalene. To better understand the mechanism for the unique toxicity profiles for both compounds, a CYP2F ortholog (CYP2F4) was isolated from rat lung and expressed using a baculovirus system. Recombinant CYP2F4 efficiently generates 1R, 2S-naphthalene oxide (K-m = 3 muM, V-max = 107 min(-1)) and the 5,6- and 7,8-epoxides of 1-nitronaphthalene (K-m = 18 muM, V-max = 25 min(-1) based on total generated glutathione conjugates). Kinetics and regio/stereoselectivity of rat CYP2F4 were indistinguishable from mouse CYP2F2. These results, combined with our recent immunomapping studies demonstrating minimal pulmonary CYP2F expression in rats, indicate that CYP2F expression is the factor most clearly associated with susceptibility to naphthalene-induced pneumotoxicity. CYP2F4 failed to display an enhanced ability to bioactivate 1-nitronaphthalene, an ability that could have potentially compensated for the lower CYP2F pulmonary expression levels in the rat, yet equal species susceptibilities. These results suggest the importance of other P450 enzymes in the epoxidation/ bioactivation of 1-nitronaphthalene. Expression of recombinant CYP2F1 ( human) yielded an immunoreactive protein with no detectable CO-difference spectrum suggesting inadequate heme incorporation.
引用
收藏
页码:857 / 865
页数:9
相关论文
共 41 条
[1]  
Agency for Toxic Substances and Disease Registry (ATSDR), 1995, TOX PROF POL AR HYDR, P1
[2]   Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR [J].
Andersen, MR ;
Farin, FM ;
Omiecinski, CJ .
DNA AND CELL BIOLOGY, 1998, 17 (03) :231-238
[3]  
[Anonymous], 2000, Natl Toxicol Program Tech Rep Ser, P1
[4]   Comparison of pulmonary/nasal CYP2F expression levels in rodents and rhesus macaque [J].
Baldwin, RM ;
Jewell, WT ;
Fanucchi, MV ;
Plopper, CG ;
Buckpitt, AR .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (01) :127-136
[5]   SPECIES VARIATION IN LUNG ANTIOXIDANT ENZYME-ACTIVITIES [J].
BRYAN, CL ;
JENKINSON, SG .
JOURNAL OF APPLIED PHYSIOLOGY, 1987, 63 (02) :597-602
[6]  
BUCKPITT A, 1992, J PHARMACOL EXP THER, V261, P364
[7]  
BUCKPITT A, 1995, MOL PHARMACOL, V47, P74
[8]  
BUCKPITT AR, 1987, DRUG METAB DISPOS, V15, P491
[9]   Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His(324)Pro) expressed by recombinant baculovirus in insect cells [J].
Evert, B ;
Eichelbaum, M ;
Haubruck, H ;
Zanger, UM .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (03) :309-318
[10]  
GROSOVSKY AJ, 1999, RES REP HLTH EFF I, V84, P1